Clinical Trials
191 trialsVaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
CPIT001
Hackensack Meridian Health
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
CAVALRY
University of Chicago
HeartPhone Cancer Survivors Trial 2019
Penn State University
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
Seattle Children's Hospital
SELECT-CAR-NK
Essen Biotech
PlaTform
The Lymphoma Academic Research Organisation
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NuCana plc
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
Chinese PLA General Hospital
ANXIN-02
The Second Hospital of Anhui Medical University
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Masonic Cancer Center, University of Minnesota
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
GENHIV
Assistance Publique - Hôpitaux de Paris
LOC-R01
Institut Curie
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Georgetown University
BAH2573-103
Essen Biotech
NTproBNP-Guide
Abramson Cancer Center at Penn Medicine
PACMAN
Princess Maxima Center for Pediatric Oncology
EBV-TCL-01
Maisonneuve-Rosemont Hospital
CAR-NK
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Thomas Jefferson University
CAR-T
Tianjin Medical University General Hospital
BAL
Insel Gruppe AG, University Hospital Bern
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Zhujiang Hospital
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Mayo Clinic
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CARTHEDRALL
University of Sao Paulo
Epi-RCHOP
The Lymphoma Academic Research Organisation
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
M.D. Anderson Cancer Center
MZL-001
The First Hospital of Jilin University
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
Columbia University
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Columbia University
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
University Hospital, Basel, Switzerland
CAR19T2
Zhujiang Hospital
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center